Strategies for surface coatings of implantable cardiac medical devices

Front Bioeng Biotechnol. 2023 May 9:11:1173260. doi: 10.3389/fbioe.2023.1173260. eCollection 2023.

Abstract

Cardiac medical devices (CMDs) are required when the patient's cardiac capacity or activity is compromised. To guarantee its correct functionality, the building materials in the development of CMDs must focus on several fundamental properties such as strength, stiffness, rigidity, corrosion resistance, etc. The challenge is more significant because CMDs are generally built with at least one metallic and one polymeric part. However, not only the properties of the materials need to be taken into consideration. The biocompatibility of the materials represents one of the major causes of the success of CMDs in the short and long term. Otherwise, the material will lead to several problems of hemocompatibility (e.g., protein adsorption, platelet aggregation, thrombus formation, bacterial infection, and finally, the rejection of the CMDs). To enhance the hemocompatibility of selected materials, surface modification represents a suitable solution. The surface modification involves the attachment of chemical compounds or bioactive compounds to the surface of the material. These coatings interact with the blood and avoid hemocompatibility and infection issues. This work reviews two main topics: 1) the materials employed in developing CMDs and their key characteristics, and 2) the surface modifications reported in the literature, clinical trials, and those that have reached the market. With the aim of providing to the research community, considerations regarding the choice of materials for CMDs, together with the advantages and disadvantages of the surface modifications and the limitations of the studies performed.

Keywords: biocompatibility; biomaterials; cardiac medical devices; infections; surface coatings.

Publication types

  • Review

Grants and funding

This project has received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No. 801342 (Tecniospring INDUSTRY) and from the Government of Catalonia’s Agency for Business Competitiveness (ACCIÓ; TECSPR19-1-0065). IR has received funding from European Union’s Horizon 2020 research and innovation program in HORIZON-RIA action (Nabiheal; Grant agreement 101092269); MICINN (Grant agreement PID 2019-105622RBI00); Instituto de Salud Carlos III (ISCIII) through the Networking Research Center on Bioengineering, Biomaterialsand Nanomedicine, CIBER-BBN; the Fundació Marató de TV3 (Nr.201812) and Generalitat de Catalunya (2021 SGR 00438). All figures were designed with BioRender.com.